TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36963800

Group type: EXPERIMENTAL
Intervention: Smartphone application with education in its use plus conventional multidisciplinary rehabilitation programme (exercises and self-management education)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional multidisciplinary rehabilitation programme (exercises and self-management education)
Number of subjects: 120
Study: 36963815

Group type: EXPERIMENTAL
Intervention: Three additional 40 µg doses administered at monthly intervals (experimental arm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single 40 µg booster vaccination at month 6 (classical arm)
Number of subjects: 120
Study: 36963820

Group type: EXPERIMENTAL
Intervention: North America
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Europe
Number of subjects: 1118
Study: 36963852

Group type: EXPERIMENTAL
Intervention: Premeal load of almonds (20 g) 30 minutes before major meals
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 66
Study: 36963903

Group type: EXPERIMENTAL
Intervention: Calorimetry-based nutritional support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommended Dietary Allowance (RDA) guidelines
Number of subjects: 0
Study: 36964012

Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 112

Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 112
Study: 36964084

Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg on day 1 and 100 mg daily on days 2 to 14
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 36964191

Group type: EXPERIMENTAL
Intervention: SBS3
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: High HRD score
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Biallelic inactivation of HR gene
Number of subjects: 223
Study: 36964415

Group type: EXPERIMENTAL
Intervention: CF + LI-featured catheter
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LI-featured catheter
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard irrigated catheter
Number of subjects: 120
Study: 36964422

Group type: EXPERIMENTAL
Intervention: CBT-TS (brief CBT for Treatment Seeking) delivered by phone
Number of subjects: 841

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 841
Study: 36964455

Group type: EXPERIMENTAL
Intervention: Data validation process through pilot audit in participating hospitals
Number of subjects: 330
Study: 36964485

Group type: EXPERIMENTAL
Intervention: Pre-radiotherapy supervised exercise
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Post-radiotherapy supervised exercise
Number of subjects: 144

Group type: COMPARATOR
Intervention: Autonomous exercise
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All groups (pre-radiotherapy, post-radiotherapy, autonomous exercise)
Number of subjects: 144
Study: 36964490

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block
Number of subjects: 160

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 160
Study: 36964529

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) with a dose of 15-24 Gy in 1 or 3 fractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery (fSRS) 35 Gy in five fractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery (fSRS)
Number of subjects: 0
Study: 36964541

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 200
Study: 36964582

Group type: EXPERIMENTAL
Intervention: ViBone VBM
Number of subjects: 0
Study: 36964590

Group type: EXPERIMENTAL
Intervention: Postoperative vasopressor infusions (PVI)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Postoperative vasopressor usage
Number of subjects: 40000
Study: 36964593

Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention in physical therapy (BMIP) plus routine exercise-based cardiac rehabilitation (exCR)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Routine exercise-based cardiac rehabilitation (RC)
Number of subjects: 170
Study: 36964608

Group type: EXPERIMENTAL
Intervention: webCHAT (single session online intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: usual driver education
Number of subjects: 150
Study: 36964614

Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided fluid deresuscitation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control (deresuscitation at physician's discretion without LUS)
Number of subjects: 1000
Study: 36964626

Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT) approximately every 6-10 weeks until delivery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 36964866

Group type: EXPERIMENTAL
Intervention: Multi-domain lifestyle intervention (including dietary counselling, strict management of cardiovascular and metabolic risk factors, and exercise training)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 456
Study: 36964872

Group type: EXPERIMENTAL
Intervention: CMAB008 3 mg/kg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Innovator infliximab 3 mg/kg
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: CMAB008
Number of subjects: 384

Group type: COMPARATOR
Intervention: Innovator infliximab
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: CMAB008 and Innovator infliximab
Number of subjects: 384
Study: 36964977

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) defined as an estimated glucose disposal rate (eGDR) ≤9.0 mg/kg/min
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Patients with ≥10 years of T1D
Number of subjects: 923

Group type: COMPARATOR
Intervention: Patients with <10 years of T1D
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 923
Study: 36965105

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 0
Study: 36965173

Group type: EXPERIMENTAL
Intervention: Convalescent COVID-19 plasma (CCP)
Number of subjects: 95
Study: 36965196

Group type: EXPERIMENTAL
Intervention: Continuous suppression (CS) strategy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Search and destroy (SD) strategy
Number of subjects: 63
Study: 36965232

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Assisted Referral to Community Care (ARC)
Number of subjects: 52
Study: 36965396

Group type: EXPERIMENTAL
Intervention: Persistent somatic symptoms
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Modifying illness perception (IP)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Individual illness perception (IP)
Number of subjects: 74
Study: 36965493

Group type: EXPERIMENTAL
Intervention: Adult-led organized group settings for children, assessed through accelerometry and video observation.
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Community data system for monitoring and feedback on physical activity.
Number of subjects: 1302
Study: 36965550

Group type: EXPERIMENTAL
Intervention: High RNT MDD group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: MDD (regardless of RNT intensity)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RNT-nonspecific findings in MDD
Number of subjects: 159
Study: 36965692

Group type: EXPERIMENTAL
Intervention: Menus with greater food weight
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Menus with higher energy density
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Daily menus meeting dietary recommendations
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Children with overweight and obesity
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Children with lower satiety responsiveness or higher food responsiveness
Number of subjects: 128
Study: 36965695

Group type: COMPARATOR
Intervention: Sterile gloves (powder-free polyvinyl chloride examination gloves)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Clean gloves (powder-free nitrile examination gloves)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Combined rates of infection (both groups)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Participants with any infection (n=11)
Number of subjects: 163
Study: 36965866

Group type: EXPERIMENTAL
Intervention: Nonreportable cell-free DNA screening results
Number of subjects: 17851

Group type: EXPERIMENTAL
Intervention: First nonreportable test
Number of subjects: 17851

Group type: EXPERIMENTAL
Intervention: Second nonreportable test
Number of subjects: 17851

Group type: EXPERIMENTAL
Intervention: Nonreportable tests
Number of subjects: 17851
Study: 36966023

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 36966179

Group type: EXPERIMENTAL
Intervention: AI analysis arm (n=38)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No-AI analysis arm (n=38)
Number of subjects: 109
Study: 36966310

Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy with deposition of corticosteroids
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intra-articular corticosteroid injections (IACSI)
Number of subjects: 80
Study: 36966349

Group type: EXPERIMENTAL
Intervention: Adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for 5 years
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard follow-up (control group)
Number of subjects: 100
Study: 36966440

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 40
Study: 36966799

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once per day for 8 weeks plus standard tuberculosis therapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard tuberculosis therapy alone (control group)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once per day
Number of subjects: 137
Study: 36966905

Group type: EXPERIMENTAL
Intervention: Third monovalent mRNA vaccines
Number of subjects: 81
Study: 36966922

Group type: EXPERIMENTAL
Intervention: AI-enabled electrocardiogram (AI-ECG)
Number of subjects: 1000
Study: 36966953

Group type: COMPARATOR
Intervention: Standard GIST (n=24)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intensive GIST (n=18)
Number of subjects: 49
Study: 36967158

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acacia gum
Number of subjects: 30
Study: 36967162

Group type: EXPERIMENTAL
Intervention: Plasma DHPPA concentration in NAFLD patients
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Increasing tertiles of plasma DHPPA
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of plasma DHPPA
Number of subjects: 1880
Study: 36967172

Group type: EXPERIMENTAL
Intervention: Supplementary feeding
Number of subjects: 1791
Study: 36967169

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (74.2% energy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-fat meal (64.6% energy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-protein meal (39.5% energy)
Number of subjects: 20
Study: 36967189

Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penne
Number of subjects: 30

Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bread
Number of subjects: 30
Study: 36967244

Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's Choice (PC) of therapy
Number of subjects: 0
Study: 36967282

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Breathe-squeeze task
Number of subjects: 14
Study: 36967281

Group type: EXPERIMENTAL
Intervention: Pholcodine exposure within a year before anaesthesia
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Occupational exposure to quaternary ammonium compounds
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Pholcodine and quaternary ammonium sIgEs
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Patients exposed to pholcodine 12 months before NMBA exposure
Number of subjects: 501
Study: 36967448

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX)
Number of subjects: 112
Study: 36967470

Group type: EXPERIMENTAL
Intervention: Predominant nocturnal AF (n = 40)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Predominant daytime AF (n = 43)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Mixed AF (n = 195)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Comparison of nocturnal vs. mixed AF
Number of subjects: 278

Group type: COMPARATOR
Intervention: Comparison of daytime vs. mixed AF
Number of subjects: 278
Study: 36967527

Group type: EXPERIMENTAL
Intervention: Initiation of glucose-lowering drugs (specific drugs not mentioned)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Metformin (in clinical pharmacokinetic trial, n=10)
Number of subjects: 1026
Study: 36967681

Group type: EXPERIMENTAL
Intervention: Asthma risk alleles in CDHR3
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Asthma risk alleles in GSDMA, GSDMB, IKZF3, ZPBP2, and ORMDL3
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Asthma risk alleles
Number of subjects: 1011
Study: 36967714

Group type: EXPERIMENTAL
Intervention: Convalescent plasma from vaccinees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Convalescent plasma from REMAP-CAP and Argentinian trials
Number of subjects: 0
Study: 36967840

Group type: EXPERIMENTAL
Intervention: Transcoronary stem cell transfer
Number of subjects: 22
Study: 36967843

Group type: EXPERIMENTAL
Intervention: Wharton jelly multipotent stem cells (WJMSCs) transcoronary transfer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 36968218

Group type: EXPERIMENTAL
Intervention: Local ablation + sorafenib
Number of subjects: 104

Group type: COMPARATOR
Intervention: Local ablation + placebo
Number of subjects: 104
Study: 36968554

Group type: EXPERIMENTAL
Intervention: 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir (30/15/40/10 mg) fixed-dose combination of granules in a capsule
Number of subjects: 36
Study: 36968629

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP < 120 mm·Hg)
Number of subjects: 3310

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP < 140 mm·Hg)
Number of subjects: 3310
Study: 36968637

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coping mechanisms
Number of subjects: 0
Study: 36968652

Group type: EXPERIMENTAL
Intervention: Mid-dose PHEN/TPM (7.5 mg/46 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Top-dose PHEN/TPM (15 mg/92 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 36968754

Group type: EXPERIMENTAL
Intervention: Step guided multicomponent interprofessional intervention program (group therapy, daily training, individual sessions)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Step guided multicomponent interprofessional intervention program
Number of subjects: 41
Study: 36969023

Group type: EXPERIMENTAL
Intervention: Moderately hypo-fractionated radiotherapy (60Gy in 24 fractions) concurrent with S-1
Number of subjects: 58
Study: 36969063

Group type: EXPERIMENTAL
Intervention: TDM-guided dosing of alectinib (intervention arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dosing of alectinib 600 mg taken twice daily with food (control arm B)
Number of subjects: 0
Study: 36969244

Group type: EXPERIMENTAL
Intervention: JE-YF17D vaccination followed by YF17D challenge
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: YF17D vaccination followed by JE-YF17D challenge
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inactivated JEV vaccine followed by YF17D challenge
Number of subjects: 70
Study: 36969338

Group type: EXPERIMENTAL
Intervention: Napabucasin plus nab-paclitaxel with gemcitabine
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Nab-paclitaxel with gemcitabine (control)
Number of subjects: 1134
Study: 36969389

Group type: EXPERIMENTAL
Intervention: Self-guided psychological Internet-delivered intervention
Number of subjects: 0
Study: 36969390

Group type: EXPERIMENTAL
Intervention: Smartphone cognitive behavioral therapy (CBT) for body dysmorphic disorder, specific dosage and duration not mentioned.
Number of subjects: 0
Study: 36969546

Group type: COMPARATOR
Intervention: Education attention control
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Treatment (manualized, family-tailored education and problem-solving adherence intervention)
Number of subjects: 27
Study: 36969704

Group type: EXPERIMENTAL
Intervention: Highest tertile of 8-isoprostane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2,3-dinor-8-F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary isoprostanes
Number of subjects: 0
Study: 36969747

Group type: EXPERIMENTAL
Intervention: ctDNA monitoring during first-line treatment
Number of subjects: 132
Study: 36969745

Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of SHP2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor cell-specific depletion of SHP2
Number of subjects: 0
Study: 36969889

Group type: EXPERIMENTAL
Intervention: 25 mg TMF
Number of subjects: 48

Group type: COMPARATOR
Intervention: 300 mg TDF
Number of subjects: 48
Study: 36969982

Group type: EXPERIMENTAL
Intervention: Mobile interventions plus nicotine replacement therapy sampling (NRT-S)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Regular text messages regarding general health
Number of subjects: 664
Study: 36970054

Group type: EXPERIMENTAL
Intervention: Gemcitabine/Nab-Paclitaxel/Xeloda (GAX) in Combination With Cisplatin and Irinotecan (GAX-CI)
Number of subjects: 12
Study: 36970056

Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg once daily for 14 days in 21-day cycles (schedule A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TAK-931 (schedule B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg once daily days 1-14 in 21-day cycles
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TAK-931
Number of subjects: 80
Study: 36970055

Group type: EXPERIMENTAL
Intervention: Palbociclib plus nab-paclitaxel
Number of subjects: 76

Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel
Number of subjects: 76

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 76
Study: 36970275

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine infusion
Number of subjects: 0
Study: 36970545

Group type: EXPERIMENTAL
Intervention: 10-week O-RAGT program in combination with usual care physiotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care physiotherapy only
Number of subjects: 34
Study: 36970876

Group type: EXPERIMENTAL
Intervention: Vevorisertib monotherapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vevorisertib plus paclitaxel
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vevorisertib plus fulvestrant
Number of subjects: 78
Study: 36970971

Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus Pegaspargase 2500 U/m, combined with Anlotinib and radiotherapy
Number of subjects: 0
Study: 36971108

Group type: EXPERIMENTAL
Intervention: Digitally delivered Acceptance and Commitment Therapy (ACT) for chronic pain, specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable, as no control group is mentioned in the abstract.
Number of subjects: 0
Study: 36971225

Group type: EXPERIMENTAL
Intervention: Refugees diagnosed with PTSD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 36971560

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor treatment
Number of subjects: 75
Study: 36971688

Group type: EXPERIMENTAL
Intervention: Combined behavioural and lifestyle interventions (dietary modification and increased physical activity)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Combined behavioural and lifestyle interventions
Number of subjects: 610
Study: 36971690

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16302
Study: 36971735

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Relapse Prevention (RP)
Number of subjects: 182
Study: 36971771

Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD [75/150 mg])
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD [75/150/300 mg])
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Any secukinumab LD
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Any secukinumab HD
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Secukinumab (both LD and HD)
Number of subjects: 320
Study: 36971816

Group type: EXPERIMENTAL
Intervention: Intraoperative leak testing group (IOLT)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No intraoperative leak testing group (NIOLT)
Number of subjects: 148
Study: 36971978

Group type: EXPERIMENTAL
Intervention: Online survey measuring pregnancy preferences, perceived CKD severity, perception of pregnancy risk, pregnancy intention, distress, social support, illness perceptions, and quality of life.
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Clinical data extracted from local databases.
Number of subjects: 315
Study: 36972022

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus paclitaxel and carboplatin
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel and carboplatin
Number of subjects: 816
Study: 36972026

Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg) plus carboplatin and paclitaxel
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 494
Study: 36972049

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sleep Education
Number of subjects: 82